Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options

Annals of Pharmacotherapy

Volumn 32, Issue 12, 1998, Pages 1353-1361

  Klepser, Michael E ^a   Lewis, Russell E ^a   Pfaller, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

Amphotericin B.; Candida; Fluconazole; Resistance

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POSACONAZOLE; RAVUCONAZOLE; VORICONAZOLE;

CANDIDA; CANDIDIASIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG FORMULATION; DRUG SENSITIVITY; FUNGUS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NEPHROTOXICITY; ORAL DRUG ADMINISTRATION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DISEASE SUSCEPTIBILITY; DRUG RESISTANCE, MICROBIAL; DRUG THERAPY, COMBINATION; FLUCONAZOLE; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS;

EID: 0032441017     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18166     Document Type: Review

References (9)

1. Banerjee SN, Emori TG, Culver DH, Gaynes RP, Jarvis WR, Horan T, et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. Am J Med 1991;91(suppl 3B):86S-9S.
2. Beck-Sagué CM, Jarvis WR, National Nosocomial Infections Surveillance System. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993;167:1247-51.
3. Wey SB, Mon M, Pfaller MA, Woolson RF, Wenzel RP. Hospital-acquired candidemia: the attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642-5.
4. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP, the SCOPE Participant Group. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn Microbiol Infect Dis 1998:30:121-9.
5. Wey SB, Mori M, Pfaller MA, Woolson RF, Wenzel RP. Risk factors for hospital-acquired candidemia. A matched case-control study. Arch Intern Med 1989;149:2349-53.
6. Bross J, Talbot GH, Maislin G, Hurwitz S, Strom BL. Risk factors for nosocomial candidemia: a case control study in adults without leukemia. Am J Med 1989:87:614-20.
7. MacDonald L, Baker C, Chenweth C. Risk factors for candidemia in a children's hospital. Clin Infect Dis 1998:26:642-5.
8. Pfaller MA. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin Infect Dis 1996;22(suppl 2):S89-94.
9. Aisner J, Schimpff SC, Sutherland JC, Young VM, Wiernik PH. Tornlopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization. Am J Med 1976;61:23-8.